Dyax Corp. Announces Expansion of Research Agreement with Trubion Pharmaceuticals, Inc.
Dyax Corp. announced that Trubion Pharmaceuticals, Inc. has exercised an option to expand its existing research agreement, which covers protein therapeutics and diagnostics discovery. In addition to the ongoing multiple-target funded research project, Dyax will now transfer its proprietary phage library to Trubion's facility for use in identifying therapeutic leads to additional targets, further enabling Trubion's ability to rapidly design and develop product candidates for a range of disease targets. Additional terms of the expanded agreement were not disclosed.
"We are excited Trubion has expanded its research agreement to further take advantage of our proprietary phage display technology," commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax. "This expanded agreement continues to validate our technology as a powerful tool for accelerating discovery and development of therapeutic agents and, additionally, confirms the success of our Licensing and Funded Research Program (LFRP)."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
